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Lymphocytes are more likely to make an immune
response if costimulatory and antigen receptors
coincidently signal; the way the signals are integrated
illustrates how a lymphocyte learns to distinguish self
from foreign antigens, and provides a model for
coincident signaling through more than one receptor.
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The most important choice a lymphocyte must make is
whether or not to mount an immune response against an
antigen. Normal responses triggered through binding of
antigen to antigen-specific receptors on B and T cells
distinguish between infectious foreign antigens, which
elicit an immune response, and self antigens, which elicit
a tolerance response. Foreign antigens are distinguished
from self antigens in part by the context of their detection
by lymphocytes. One way that lymphocytes detect the
context of the antigen is through the use of costimulatory
receptors, such as CD19 on B cells and CD28 on T cells. 
In molecular terms, the lymphocyte must process signals
through both its antigen receptor and coreceptor. The way
in which these signals are integrated is important, both in
understanding immune responses and as a paradigm for
understanding the coordination of signaling by two or
more cell-surface receptors. In recent years, it has been
shown that autoimmune responses to self antigens can be
precipitated by disregulation of the CD19 or CD28 path-
ways [1–3]. We shall consider the similar functions of
CD28 on T cells and CD19 on B cells as costimulatory
receptors, and discuss how signals generated by these
coreceptors change the quality and quantity of signals
through the antigen receptor. 
Tolerance and immunity decisions in lymphocytes
When T cells and B cells bind their specific antigen in the
appropriate context, they make an ‘immunity’ response.
This is characterized by proliferation for both T and B cells.
The B cells go on to become antibody-secreting plasma
cells; the T cells make cytokines, such as interleukin-2 
(IL-2), and, in the case of the cytotoxic T cells, kill targets.
But if antigen is bound at the wrong time in development —
for example, to developing T cells in the thymus — or if
antigen is bound in the wrong context — for example,
without costimulatory signals — the lymphocyte makes a
‘tolerance’ response. The simplest tolerance response is to
die; this happens to maturing B cells in the bone marrow
and to thymocytes undergoing negative selection in the
thymus. Alternatively, B and T cells may become function-
ally tolerant, or ‘anergic’ to further antigenic stimulation.
Anergic T cells proliferate weakly and make little IL-2 in
response to antigen, but can make other cytokines [4].
Anergic B cells also proliferate weakly in response to antigen
stimulation, but still change their migratory patterns [5].
Upon antigen binding, a lymphocyte must decide whether
to mount an immune response or to become tolerant.
As mentioned above, one factor that contributes to the
tolerance or immunity decision is the developmental stage
of the lymphocyte when it encounters an antigen that it
recognizes. Another important factor is the nature of the
antigen — its concentration, avidity for the lymphocyte’s
antigen receptor, and the duration of exposure. A third
factor is the context in which the antigen is detected or,
specifically, what costimulatory molecules are associated
with the antigen. Ligands for costimulatory receptors are
produced in response to pathogenic challenge. These
ligands help to indicate the presence of a foreign invader
that would require an immune response from the specific
T cell or B cell binding antigen in that region.
CD28 costimulation of T cells
The costimulatory receptor CD28 forms a transmembrane
homodimer that is present on most T cells. CD28 binds to
B7.1 and B7.2, surface proteins present on antigen-
presenting cells, such as B cells (Figure 1). B7 family
members are produced in response to foreign infection
and thus indicate the need for an immune response.
Stimuli that lead to upregulation of B7 proteins include
structural components of bacteria, such as lipopolysaccha-
ride, antigen binding to B cells, and tumor necrosis factor
α (TNFα), which is produced following cell injury [6].
When a T cell is acutely stimulated by antigen through its
T-cell antigen receptor, and at the same time costimulated
by B7.1 or B7.2 through the CD28 coreceptor, the com-
bined signal stimulates the T cell to produce IL-2 and
proliferate, and prevents anergy [7,8]. 
The key role of CD28 stimulation has been firmly estab-
lished by a variety of experimental approaches in mice.
Blocking the ligation of CD28 diminishes T-cell immune
responses to a range of stimuli in vivo [6]. Early experi-
ments demonstrated the importance of the CD28–B7 inter-
action for transplant rejection. Since then, mice lacking
CD28 or expressing a soluble CD28 antagonist (CTLA4Ig)
have shown deficient immune responses. The suppression
of autoimmune disease by blocking CD28 ligation has
been shown in several mouse models, including mice with
autoimmune diabetes or experimental autoimmune
encephalomyelitis [6]. Conversely, expression of B7.1 or
B7.2 in an inappropriate context, such as on pancreatic
islet β cells [2,3] or self-tolerant B cells (our unpublished
data), can provoke autoimmune responses when tolerance
would normally be the outcome.
CD19 costimulation of B cells
Antigen binding to the B-cell antigen receptor causes
analogous biochemical and biological effects to antigen
binding to the T-cell receptor. B-cell receptor ligation
results in B-cell proliferation and induces expression of 
T-cell costimulatory molecules such as B7.2, priming the
B cell to produce antibodies. Like CD28 on T cells,
activation of the CD19 costimulatory receptor complex on
B cells changes the outcome of antigen–receptor ligation.
CD19 is a transmembrane protein made constitutively by
B cells. On its own, CD19 may act as a receptor for an as
yet unidentified ligand. But in association with the
complement-binding chain CD21, CD19 forms the signal-
ing subunit of the CR2 complement receptor (Figure 1)
[9]. The complement system is a proteolytic cascade of
interacting serum proteins that is selectively triggered by
distinctive properties of foreign microorganisms, such as
charge, glycosylation patterns or the absence of anti-
complement regulatory proteins. Once triggered, cleavage
products of the third complement component, C3b and
C3d, are covalently attached to foreign antigens, tagging
them for destruction (C3b) or for immune responses (C3d).
When a B cell is acutely stimulated by antigen through its 
B-cell receptor and simultaneously costimulated by attached
C3d via its complement receptor complex, the combined
signal synergistically augments B-cell activation and anti-
body production [10]. Antibody responses are markedly
reduced in animals lacking C3, CD21 or CD19, or when
C3 is depleted or blocked by soluble fusion proteins
[9,11]. These results parallel the effects of blocking the
B7–CD28 pathway in T cells. Moreover, just as inappro-
priate expression of B7 can provoke autoimmunity in T
cells, disregulated expression of CD19 can provoke spon-
taneous autoantibody production by B cells that would
otherwise remain tolerant [1].
Signaling pathways affected by coreceptors
How do CD28 and CD19 alter the way B and T cells
respond to antigen, shifting the balance away from
tolerance and towards immunity? This active area of
research is sometimes controversial, in part because of the
range of cell models and stimuli used. Nevertheless,
biochemical studies strengthen the parallels between
CD28 and CD19, indicating that both coreceptors change
the quality and quantity of antigen-receptor signals.
Antigen receptors on B and T cells activate a similar array
of intracellular signaling cascades, including those involving
members of the mitogen activated protein (MAP) kinase
family, extracellular-signal-related kinase (ERK) and Jun
N-terminal kinase (JNK), and nuclear translocation of the
transcription factors NF-κB and NF-AT. Each of these
pathways is regulated differently and, to some extent, inde-
pendently. The spectrum of pathways activated by antigen
receptors is shifted in one direction during tolerance induc-
tion. For example, in anergic B cells which have become
tolerant to self antigens, the JNK and NF-κB pathways are
not activated in response to B-cell receptor ligation, but the
ERK and NF-AT pathways are activated continuously [12].













































Binding of coreceptors on B and T cells promotes immunity responses at the expense of tolerance responses.
In anergic T cells, T-cell receptors lose their capacity to
activate the JNK, ERK and NF-κB pathways, but they can
still stimulate the NF-AT pathway [13–15].
CD28 and CD19 appear to augment the same pathways
that are diminished in anergic lymphocytes. CD28 stimu-
lation greatly augments activation by the T-cell receptor
of JNK and NF-κB, while having no detectable effect on
ERK activation [16,17]. In conjunction with B-cell recep-
tor signaling, CD19 stimulation can lead to activation of
both JNK and ERK [18,19]. The effect of CD19 costimu-
lation on NF-κB is not yet known, although crosslinking
CD19 alone can upregulate NF-κB DNA-binding activity
in a pre-B-cell line [20]. How CD28 and CD19 augment
MAP kinase and NF-κB pathways is unclear; both can
activate phosphatidylinositol 3-kinase, but it is still
debated whether or not this mediates their costimulatory
effects [9,21,22]. Other molecules, such as Vav, have been
implicated in coreceptor signaling [23].
Conclusions
The parallels between the CD19 and CD28 pathways, both
functional and molecular, begin to reveal the details of how
immunity and tolerance responses are balanced. Acquisi-
tion of tolerance by anergy weakens antigen receptor sig-
naling pathways, such as those involving JNK and NF-κB,
whereas both CD19 and CD28 can enhance antigen-recep-
tor signaling by strengthening these same pathways.
Because coreceptor ligands are induced by foreign infec-
tions, coreceptors help lymphocytes learn to be tolerant to
self and generate immune responses to foreign pathogens. 
This is reminiscent of neurological learning, where coinci-
dent signaling is also required to strengthen synaptic
responses. The induction of the form of synaptic plasticity
known as long-term potentiation, thought to underlie
some forms of learning and memory, requires co-activation
of two different subtypes of glutamate receptor [24]. Coin-
cident signaling through more than one receptor is impor-
tant in many systems; understanding how signals are
integrated from different receptors holds the key to a
better understanding of cell-fate decisions in the context
of adaptive biological processes.
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